Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.

Abstract

CYP2C9 catalyses the biotransformation of the oral anticoagulants S-warfarin and R- and S-acenocoumarol. According to data obtained in vitro, phenprocoumon is also metabolized by CYP2C9 but the impact of the CYP2C9 polymorphism on phenprocoumon pharmacokinetics has not been studied. Twenty-six healthy heterozygous and homozygous carriers of the CYP2C9… (More)

Topics

Cite this paper

@article{Kirchheiner2004EffectsOC, title={Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.}, author={Julia Kirchheiner and M Ufer and Ev-Charlotte Walter and Bernd Kammerer and Rainer Kahlich and Christian Meisel and Matthias Schwab and Christoph H. Gleiter and Anders Rane and Ivar Roots and J{\"u}rgen Brockm{\"o}ller}, journal={Pharmacogenetics}, year={2004}, volume={14 1}, pages={19-26} }